Time to Buy: Dendreon?

In this entry, David and Austin focus on Dendreon, which saw shares get clobbered in the month of July. Is it time to invest in this cutting-edge company on the cheap, or is the poor month a sign of further troubles ahead? Watch and find out.

Many investors are attracted to Dendreon and biotechs like it since they hold the allure of substantial short-term gains. But there is more than one approach to building long-term wealth and retiring well. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some winning wealth-building strategies. Click here to keep reading.

Austin Smith and Dave Williamson have no positions in the stocks mentioned above. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (1) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On September 17, 2012, at 3:29 PM, lebronz wrote:

    http://www.fool.com/investing/general/2012/09/15/heres-what-...

    The comment summary on DNDN I placed in your colleague (Ms. Selena) Fewlish article applies to you too Dave.

    Your tactic of talking negative about a promising biotech company (fishing for "article hits" from Dendreonites) isn't working too well since I'm the only one commenting on your articles..

    Try having your future fewlish articles/videos on DNDN help the average investor become aware of DNDN's future value and potential because they'll maybe beneift financially..., along with the company trying to treat the 1000's of men dying from prostate cancer.

    Good luck Sir!

    L

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1981569, ~/Articles/ArticleHandler.aspx, 9/19/2014 6:06:03 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement